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ABSTRACT
Objective Although β-blockers are an established
therapy in heart failure (HF) guidelines, including for
patients with chronic obstructive pulmonary disease
(COPD), there remain concerns regarding
bronchoconstriction even with cardioselective β-blockers.
We wished to assess the real-life use of β-blockers for
patients with HF and comorbid COPD.
Methods We evaluated data from the Optimum Patient
Care Research Database over a period of 1 year for co-
prescribing of β-blockers with either an ACE inhibitor
(ACEI) or angiotensin-2 receptor blocker (ARB) in
patients with HF alone versus HF+COPD. Association
with inhaler therapy was also evaluated.
Results We identiﬁed 89 861 patients with COPD,
24 237 with HF and 10 853 with both conditions. In
patients with HF+COPD, the mean age was 79 years;
60% were male, and 27% had prior myocardial
infarction. Of patients with HF+COPD, 22% were taking
a β-blocker in conjunction with either ACEI/ARB
(n=2416) compared with 41% of patients with HF only
(n=10 002) (adjusted OR 0.54, 95% CI 0.51 to 0.58,
p<0.001). Among HF+COPD patients taking inhaled
corticosteroid (ICS) with long-acting β-agonist (LABA)
and long-acting muscarinic antagonist, 27% of patients
were taking an ACEI/ARB with β-blockers (n=778)
versus 46% taking an ACEI/ARB without β-blockers
(n=1316). Corresponding ﬁgures for those patients
taking ICS/LABA were 20% (n=583) versus 48%
(n=1367), respectively.
Conclusions These data indicate a substantial unmet
need for patients with COPD who should be prescribed
β-blockers more often for concomitant HF.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is
one of the world’s leading causes of morbidity and
mortality.1 2 Cardiovascular comorbidity is common
in patients with COPD, at least partly due to the
common risk factor of cigarette smoking. The
prevalence of COPD in patients with heart failure
(HF) ranges from 11%–52% to 9%–41% in North
American and European patients, respectively.3
There is a need to evaluate the drugs used in the
treatment of common comorbidities in COPD, in
particular the putative effects of β-blockers on the
cardiovascular burden and its associated impact on
mortality4 5 β-blockers are established in HF man-
agement guidelines, which reinforce their use in
patients with concomitant COPD.6 However, aside
from the use of long-term oxygen therapy, there
are no respiratory drugs that have been shown to
have a signiﬁcant impact on mortality in COPD.7
COPD management guidelines also state that the
beneﬁts of selective β-1 antagonists in HF outweigh
potential risks, even in patients with severe
COPD.7 Because of concerns regarding potential
bronchoconstriction (especially in patients with
more severe COPD), primary and secondary care
physicians remain somewhat reticent to prescribe
β-blockers in COPD. In a retrospective study of
1603 patients with COPD and a history of myocar-
dial infarction (MI), 22% were prescribed a beta
-blocker on admission to hospital and 55% of
patients were not prescribed one β-blocker.8
Initiating treatment with β-blockers in HF and
COPD is not simple. It requires careful initial dose
titration over a period of weeks, along with moni-
toring of heart rate, supine and standing blood
pressure and spirometry. Moreover, β-blockers tend
to be less well tolerated in older patients with
comorbidities, such as diabetes, peripheral vascular
disease and renal impairment, who are more prone
to postural hypotension. This may further com-
pound the reluctance to prescribe β-blockers in HF
and COPD, especially in a busy outpatient setting.
Retrospective observational data have shown puta-
tive beneﬁcial effects of β-blockade in patients with
COPD.9 A meta-analysis of 15 retrospective studies
including 21 596 COPD patients shows pooled esti-
mates for mortality reduction with β-blockers of
28% and for exacerbations, 38%.10 The mortality
reduction was 36% in those patients with coronary
heart disease and 26% in those with HF.
Despite compelling observational data support-
ing the use of β-blockers in COPD, there are to
date no prospective long-term randomised trials
looking at either mortality or exacerbations in
patients with cardiovascular disease and COPD. We
wished to evaluate real-life co-prescribing of
β-blockers with either ACE inhibitors (ACEI) or
angiotensin-2 receptor blockers (ARB) in patients
with HF and COPD and their association with
inhaler therapy. We report here what we believe to
be the largest study to date, investigating the use of
β-blockers in patients with COPD and HF managed
in primary and/or secondary care.
METHODS
The Optimum Patient Care Research Database
(OPCRD) is a large, bespoke electronic database
comprising anonymous, longitudinal medical
record data for over 2.4 million patients from over
525 primary care practices across the UK. The
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OPCRD has received a favourable opinion from the Health
Research Authority of the UK National Health Service for clin-
ical research use (REC reference: 15/EM/0150) and is used fre-
quently for pharmacoepidemiological studies. The study is
registered at encepp.eu, reference: ENCEPP/SDPP/11387.
OPCRD was used to identify patients with quality outcome
framework (QOF; the UK national quality improvement initia-
tive and pay-for-performance scheme)11 diagnostic Read codes
for COPD and/or HF who had at least 1 year of data available.
We excluded any patients with COPD who did not receive any
COPD therapy or who received both selective and non-
selective β-blockers during their most recent year of data avail-
able from the database (ﬁgure 1). Patients with HF alone were
compared with patients with both HF and COPD for prescrip-
tions of ACEI/ARB and β-blockers, using the patient’s most
recent year of data from the database in the study period from
1 November 1988 to 1 August 2015 (1-year study period).
The database was accessed on 24 September 2015. Analysis
was also split by New York Heart Association (NYHA) classes
1–2 and 3–4. Furthermore, for patients with a diagnosis of
both COPD and HF, the association of β-blocker use with
inhaler therapy as a proxy for COPD disease severity, namely,
dual therapy with inhaled corticosteroid (ICS) and long-acting
β-agonist (LABA), triple therapy with the addition of long-
acting muscarinic antagonist (LAMA), as well as short-acting
β-agonist (SABA) or short-acting muscarinic antagonist
(SAMA) were assessed. The proportion of patients using select-
ive and non-selective β-blockers was assessed for the total
population and comparative groups.
Data analysis
Age and year of study period were assessed at the end of the
1-year study period. HF and COPD treatments were assessed
over the 1-year study period. Body mass index (BMI), forced
expiratory volume in 1 s (FEV1), global initiative for chronic
obstructive lung disease (GOLD) stage and NYHA class were
assigned using the most recent value recorded in the database.
Patients without a valid NYHA code were assigned a proxy
NYHA class based on breathlessness coded in the database.
Presence of prior MI or asthma diagnosis was assessed at any
time during or prior to the period of study. Treatments for HF
were compared between groups using logistic regression for
unadjusted analyses and using a two-level generalised linear
model with random intercepts for adjusted analyses accounting
for clustering by general practice (GP). ORs, 95% CIs and
p values are reported.
Analyses were conducted using IBM Statistical Package for the
Social Sciences (SPSS) V.23 (SPSS Statistics; IBM, Somers,
New York, USA) and Statistical Analysis System (SAS) V.9.3 (SAS
Institute, Cary, North Carolina, USA).
Figure 1 Patient inclusion and exclusion criteria. COPD, chronic obstructive pulmonary disorder; HF, heart failure; OPCRD, Optimum Patient Care
Research Database.
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RESULTS
A total of 89 861 patients being treated for COPD, 24 237 with
HF and 10 853 with both HF and COPD were identiﬁed. In
patients who had HF and COPD, mean (SD) age was 79 (9)
years; 60% were males, 27% had a prior MI and 32% had an
asthma diagnosis. In those with HF alone, corresponding ﬁgures
were 78 (12) years, 53% males, 30% prior MI and 26% asthma
diagnosis. The median (IQR) of the study period for patients
with HF and COPD was 2010 (2005–2013) and for patients
with HF only was 2012 (2009–2014). Comparing patients with
HF versus HF and COPD, respective mean (SD) values for BMI
were 29 (6) versus 28 (6), and for FEV1% of predicted were
78% versus 57%.
Data for COPD severity grading in patients with HF and
COPD comprised GOLD stage A (21%), B (25%), C (19%) and
D (35%). Grading according to NYHA showed: 38% class 1,
26% class 2, 27% class 3 and 10% class 4 in patients with HF
and COPD, with the corresponding ﬁgures in HF alone being
54%, 26%, 15% and 5%.
Of those taking β-blockers (irrespective of ACEI and ARB
use; n=24 566), there were 21 926 (89%) patients who were
receiving cardioselective β-blockers, the most common being
bisoprolol (77%) and atenolol (16%), and 2640 (11%) receiving
non-selective β-blockers, the most common being carvedilol
(45%).
Data according to diagnosis and HF treatment are shown in
table 1. Patients with HF and COPD were more likely to be
taking an ACEI/ARB without a β-blocker than patients with HF
alone (OR=2.18, 95% CI 2.08 to 2.29, p <0.001). After
adjustment for confounders (year of study period, age, BMI,
gender, prior MI, asthma diagnosis) and allowing for clustering
by GP practice, patients with HF and COPD remained more
likely to be taking ACEI/ARB without a β-blocker than patients
with HF alone (OR=1.92, 95% CI 1.81 to 2.02, p<0.001).
Those with HF and COPD were less likely to be prescribed a
β-blocker in conjunction with either ACEI/ARB when compared
with patients with HF alone (OR=0.41, 95% CI 0.39 to 0.43,
p<0.001) (ﬁgure 2). Again, after adjustment for confounders
(as above) and allowing for clustering by GP practice, patients
with HF and COPD remained less likely to be prescribed a
β-blocker in conjunction with either ACEI/ARB when compared
with patients with HF alone (OR=0.54, 95% CI 0.51 to 0.58,
p<0.001). Use of cardioselective β-blockers was similar in those
with HF taking a β-blocker plus ACEI/ARB (n=9049 (90%))
and patients with HF and COPD who were taking a β-blocker
plus ACEI/ARB (n=2191 (91%)).
At all levels of dyspnoea, patients with HF and COPD
were less likely to be prescribed a β-blocker in combination
with ACEI/ARB than those with HF alone, for NYHA classes
1/2 (OR=0.43, 95% CI 0.40 to 0.46, p<0.001) and for
NHYA classes 3/4 (OR=0.36, 95% CI 0.32 to 0.41,
p<0.001) (ﬁgure 2). After adjustment for confounders (year
of study period, age, gender, prior MI, asthma diagnosis)
and allowing for clustering by GP practice, patients with HF
and COPD remained less likely to be prescribed a β-blocker
in combination with ACEI/ARB than those with HF alone
(for NYHA classes 1/2 and 3/4 respectively: OR=0.51, 95%
CI 0.47 to 0.56, p<0.001; OR=0.39, 95% CI 0.34 to 0.45,
p<0.001).
Data according to COPD inhaled therapy and HF treatment
for those with diagnosis of both COPD and HF are shown in
table 2 and ﬁgure 3. At all levels of COPD treatment intensity,
use of ACEI/ARB with β-blocker was less likely than the use of
ACEI/ARB without β-blocker in those with HF and COPD. In
patients with HF and COPD on triple inhaler therapy with ICS/
LABA/LAMA, there were 27% taking ACEI/ARB with β-blocker
versus 46% taking ACEI/ARB without β-blocker. Corresponding
ﬁgures for those patients on dual inhaler therapy with ICS/
LABA were 20% versus 48%, and for those taking only SABA
or SAMA, 21% versus 41%. Of patients who were taking a
β-blocker plus ACEI/ARB, 696 (89%) were taking a cardioselec-
tive β-blocker and triple inhaler therapy, compared with 533
(91%) of patients on dual inhaler therapy and 395 (93%) taking
only SABA or SAMA.
DISCUSSION
The results of the present study showed that the use of
β-blockers in conjunction with ACEI/ARB was signiﬁcantly
lower in patients with HF and COPD than in patients with HF
alone. Furthermore, in those patients with HF who had more
severe concomitant COPD receiving ICS/LABA/LABA, the pre-
scribing of β-blockers in conjunction with ACEI/ARB was 41%
lower in comparison with prescribing of ACEI/ARB alone. In
patients with moderately severe COPD receiving ICS/LABA, the
use of β-blockers with ACEI/ARB was 58% lower, while in the
patients with mildest COPD taking SABA/SAMA, its use was
49% lower. These ﬁndings highlight underuse of β-blockers in
COPD for concomitant treatment of HF across a wide range of
COPD disease severities. This is important in view of recent
retrospective data which have demonstrated that the beneﬁts of
β-blockers in reducing exacerbations occur regardless of the
severity of COPD.12 In a study looking at the use of ivabradine
in HF,13 post hoc analysis revealed that use of β-blockers was
lower in patients with HF and concomitant COPD, and that
these patients had a worse prognosis.
Underuse of β-blockers in patients with HF and COPD
appears to be related to severity of dyspnoea with the ORs for
β-blocker use being lower for NHYA classes 3–4 compared with
classes 1–2, while COPD severity appears not to be a deterrent
to prescribing β-blockers for HF.
There is a reticence to prescribe β-blockers for patients with
COPD who have coronary artery disease. Egred et al14 reported
Table 1 HF Treatment According to Diagnosis
HF treatment*
TotalDiagnosis groups None ARB and/or ACEI β-blocker only β-blocker and ACEI and/or ARB
COPD, n (%) 55 581 (61.9) 24 636 (27.4) 3918 (4.4) 5726 (6.4) 89 861 (100)
HF, n (%) 5709 (23.6) 6576 (27.1) 1950 (8.1) 10 002 (41.3) 24 237 (100)
COPD and HF, n (%) 3019 (27.8) 4864 (44.8) 554 (5.1) 2416 (22.3) 10 853 (100)
*Considering ARB, ACEI and β-blocker prescriptions only.
ACEI, ACE inhibitor; ARB, angiotensin-2 receptor blockers; COPD, chronic obstructive pulmonary disease; HF, heart failure.
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Table 2 HF Treatment According to COPD Therapy for Patients With HF and COPD Diagnoses
HF treatment
TotalCOPD therapy groups* for patients with COPD and HF None ARB and/or ACEI β-blocker only β-blocker and ACEI and/or ARB
SABA or SAMA only, n (%) 639 (32.1) 814 (40.8) 115 (5.8) 426 (21.4) 1994 (100)
LABA or LAMA, n (%) 218 (21.0) 407 (39.2) 60 (5.8) 354 (34.1) 1039 (100)
LABA+ICS, n (%) 757 (26.6) 1367 (48.0) 140 (4.9) 583 (20.5) 2847 (100)
LABA+LAMA, n (%) 18 (17.1) 43 (41.0) 7 (6.7) 37 (35.2) 105 (100)
LAMA+ICS, n (%) 26 (15.6) 79 (47.3) 6 (3.6) 56 (33.5) 167 (100)
LABA+LAMA+ICS, n (%) 559 (19.7) 1316 (46.5) 180 (6.4) 778 (27.5) 2833 (100)
ICS only, n (%) 754 (42.0) 816 (45.5) 45 (2.5) 179 (10.0) 1794 (100)
*Considering SABA, SAMA, LABA, LAMA and ICS prescriptions only.
ACEI, ACE inhibitor; ARB, angiotensin-2 receptor blockers; COPD, chronic obstructive pulmonary disease; HF, heart failure; ICS, inhaled corticosteroid; LABA, long-acting β-agonist;
LAMA, long-acting muscarinic antagonist; SABA, short-acting β-agonist; SAMA, short-acting muscarinic antagonist.
Figure 2 Prescription of β-blocker
(BB) and ACEI (ACE inhibitor) or
angiotensin-2 receptor blocker (ARB)
for patients with heart failure (HF)
alone versus patients with HF and
chronic obstructive pulmonary disease
(COPD)—showing data for all patients
and split by New York Heart
Association (NYHA) class. Data for
adjusted ORs are shown with 95% CI.
Figure 3 Use of β-blockers in chronic obstructive pulmonary disease/heart failure according to inhaler therapy. Dark bars depict patients taking
ACE inhibitor (ACEI)/ angiotensin-2 receptor blocker (ARB) without β-blockers, while lighter bars depict patients taking ACEI/ARB with β-blockers.
The absolute numbers of patients are also shown. Error bars depict 95%CI. Also see table 2 for additional numerical data. ICS, inhaled
corticosteroids; LABA, long-acting β-2 agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β-2 agonist; SAMA, short-acting
muscarinic antagonist.
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that 64% of patients without COPD and acute coronary
syndrome (ACS) were prescribed β-blockers, while the prescrip-
tion was only to 16% of patients with COPD/ACS. A diagnosis
of COPD was documented as the reason for withholding
β-blockers in 33% of patients not receiving β-blockers, and non-
cardiologists were 40% less likely to prescribe β-blockers. Chen
et al15 reported that after an acute MI, elderly patients were
62% less likely to be prescribed β-blockers if they had a history
of treated COPD or asthma.
Bronchoconstriction from β-blocker use is due to antagonism
of prejunctional and postjunctional β-2 receptors,16 which
uncovers cholinergic tone resulting in airway constriction.
Hence, LAMAs may serendipitously prevent bronchoconstric-
tion induced by β-blocker.17 In this study, 89% of patients were
taking cardioselective β-blockers, the most common being biso-
prolol. One concern among prescribers is β-1 selective antago-
nists potentially exhibiting a small degree of dose-related β-2
receptor blockade.17 18 In a randomised controlled trial of 27
patients with HF who had concomitant moderate-to-severe
COPD, there was a 190 mL signiﬁcant difference in FEV1
between bisoprolol and placebo after 4 months of treatment.18
In patients with mild-to-moderate COPD, there was a signiﬁcant
increase in methacholine-induced airway hyper-reactivity after
treatment with metoprolol or propranolol, but not celiprolol, in
comparison with placebo.19 In 2712 patients with COPD who
were followed over 4.3 years, there was no adverse effect of
cardioselective β-blockade on either FEV1 or forced vital cap-
acity, even in patients with the most severe COPD who were
receiving inhaled triple therapy.9 In a meta-analysis of trials with
cardioselective β-blockers, there was no signiﬁcant change in
FEV1 compared with placebo after a single or chronic dosing,
while the FEV1 response to β-2 agonists was not affected.
20 The
β-blockers currently licensed for HF are the β-1 selective biso-
prolol, nebivolol, metoprolol and the non-selective carvedilol.
Gradually titrating up the dose of β-blocker to improve cardio-
vascular and pulmonary tolerability is important. Bisoprolol
exhibits a higher in vitro β-1/2 receptor selectivity ratio (14:1)
compared with atenolol (5:1) or metoprolol (2:1).21
We found that the use of non-selective β-blockers such as car-
vedilol was about 10%, irrespective of the presence of concomi-
tant COPD. This can perhaps be explained by the reticence of
clinicians to use non-selective β-blockers in general, along with a
lack of evidence to support any difference in efﬁcacy in HF
compared with selective antagonists. Carvedilol blocks both
cardiac β-1 and β-2 receptors and causes peripheral vasodilata-
tion due to α-receptor antagonism. The antioxidant activity of
carvedilol may explain why in one trial it was found to be
superior to metoprolol in patients with HF.22 A 6-week study
comparing bisoprolol, metoprolol and carvedilol in patients
with COPD and HF showed that central augmented pressure
(a measure of cardiac afterload) and levels of N-terminal brain
natriuretic peptide (a marker of left ventricular function) were
both lower with carvedilol and that it also reduced FEV1.
23
However, in a post hoc analysis of 2670 patients with HF, there
were no differences between selective and non-selective
β-blockers in terms of lower mortality or rehospitalisation in
patients with and without COPD.24 A small retrospective obser-
vational study from Japan showed the use of bisoprolol was
associated with fewer exacerbations than carvedilol in patients
with COPD and HF.25 Ivabradine may be used as an alternative
to produce heart rate reduction in HF,26 but does not confer
other beneﬁcial properties of β-blockers.
It is also important to consider the potential impact of β-2
receptor genotype on the response to β-blockers in COPD.
Patients with persistent asthma who possess one or two copies
of the arginine-16 β-2 receptor polymorphism are more prone
to propranolol-induced bronchoconstriction,27 while the same
polymorphism confers a worse outcome on survival in patients
who are receiving metoprolol post ACS.28 However, in another
post hoc analysis of patients with HF treated with metoprolol
or carvedilol, no association with survival was seen for the
arginine-16 polymorphism.29
COPD and HF often coexist in patients, and indeed, both
often coexist with other comorbidities. We hypothesised that the
underuse of β-blockers in patients with comorbid COPD and HF
may occur because doctors perceive that they will prevent drug
interactions. Further research is required into other comorbid
conditions that inﬂuence underuse of β-blockers.
Study limitations
While the ﬁndings reﬂect real-life prescribing patterns, and the
data examined are from recent years, our data should be inter-
preted with some caution due to the retrospective nature of the
analysis. For example, some patients were receiving ICS as
monotherapy or in combination with a LAMA, though this is
not approved for COPD. However, these ﬁndings are consistent
with the results of prior research indicating that COPD is often
not treated according to GOLD or UK national guidelines.30
The QOF codes for identifying patients with COPD and HF are
reliant on the accuracy of initial diagnosis. Whether patients
were prescribed β-blockers in a primary or secondary care
setting, or indeed whether data originated from cardiology or
pulmonology specialists could not be ascertained. The dataset
does not contain any information on pulmonary function out-
comes; hence, long-term safety remained unassessed.
As the study period spans 27 years from 1988 to 2015, we
acknowledge that coding accuracy, policy and practice will have
changed over this period, and as such we have adjusted for study
period in the analyses where appropriate. However, in terms of
comparison between comorbid COPD/HF and HF-alone groups,
we do not expect any bias as the median (IQR) of the most recent
data available for the two groups was similar: HF and COPD––
2010 (2005–2013), and patients with HF only––2012 (2009–
Key messages
What is already known on this subject?
Current guidelines recommend the use of cardioselective
β-blockers for heart failure (HF) in patients with chronic
obstructive pulmonary disease (COPD). However, primary and
secondary care physicians still remain reticent to prescribe
β-blockers because of concerns regarding potential
bronchoconstriction, especially in more severe patients.
What might this study add?
The results of this study showed that the use of β-blockers in
conjunction with ACE inhibitor (ACEI)/angiotensin-2 receptor
blocker (ARB) was signiﬁcantly lower in patients with HF and
COPD than in patients with HF alone, irrespective of the severity
of COPD.
How might this impact on clinical practice?
There is an unmet need in terms of underuse of β-blockers in
patients with HF and COPD, in turn suggesting that prospective
randomised controlled trials are required to determine the
beneﬁt–risk ratio of β-blockers in such patients.
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2014). Additionally, QOF was introduced in 2004 and <10% of
patients from either cohort had their most recent data before
2004. The QOF Read codes, which are part of the UK national
quality improvement initiative and pay-for-performance scheme,
ensure good reporting of the chosen diseases, which includes
COPD and HF.
Future studies should link prescribing of β-blockers with
ACEI/ARB in patients with HF and COPD to outcomes such as
mortality, hospital admissions or oral steroid courses. Although
we did not have Read codes for aldosterone antagonists, these
drugs are used as add-on therapy to ACEI to obviate aldosterone
escape in NHYA class 3/4.
In summary, our ﬁndings suggest that β-blockers are currently
being underused in patients with HF and COPD, irrespective of
the amount of inhaler therapy. Further studies are required to
investigate the reasons for these prescribing patterns and whether
they might differ between cardiologists and pulmonologists.
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